%0 Journal Article %1 noKey %A Prokopiou, E.M. %A Ryder, S.A. %A Walsh, J.J. %D 2013 %I Springer Netherlands %J Angiogenesis %K Angiogenesis Combination Conjugates Hybrids Tumour Vascular agents disrupting myown therapy vasculature %N 3 %P 503-524 %R 10.1007/s10456-013-9347-8 %T Tumour vasculature targeting agents in hybrid/conjugate drugs %U http://dx.doi.org/10.1007/s10456-013-9347-8 %V 16 %X Tumour vasculature targeting has been a very active area of cancer drug discovery over the last decade. Growth of solid tumours beyond a certain point requires a sufficient blood supply in order for them to develop and metastasise. While novel anti-angiogenic and vascular disrupting agents represent an important contribution to the armoury of anti-cancer agents they nevertheless usually require combination with standard cytotoxic therapy in order to demonstrate positive clinical outcomes. In line with this consensus, a new concept has arisen, namely the design of functional hybrids where at least one component of the design targets a tumour angiogenic/vasculature pathway. This review will outline examples of such hybrid/conjugate-based approaches. Emphasis will be placed on their preclinical evaluation with particular focus on the RGD/NGR-conjugates, heparin-related hybrids and antibody-drug conjugates. In conclusion, the benefits and shortcomings of hybrids under development will be discussed in the context of future directions and applications.

@article{noKey, abstract = {Tumour vasculature targeting has been a very active area of cancer drug discovery over the last decade. Growth of solid tumours beyond a certain point requires a sufficient blood supply in order for them to develop and metastasise. While novel anti-angiogenic and vascular disrupting agents represent an important contribution to the armoury of anti-cancer agents they nevertheless usually require combination with standard cytotoxic therapy in order to demonstrate positive clinical outcomes. In line with this consensus, a new concept has arisen, namely the design of functional hybrids where at least one component of the design targets a tumour angiogenic/vasculature pathway. This review will outline examples of such hybrid/conjugate-based approaches. Emphasis will be placed on their preclinical evaluation with particular focus on the RGD/NGR-conjugates, heparin-related hybrids and antibody-drug conjugates. In conclusion, the benefits and shortcomings of hybrids under development will be discussed in the context of future directions and applications.}, added-at = {2013-07-31T21:54:28.000+0200}, author = {Prokopiou, E.M. and Ryder, S.A. and Walsh, J.J.}, biburl = {https://www.bibsonomy.org/bibtex/2c0854fca60dcfbadd2dae42825264d33/sryder}, doi = {10.1007/s10456-013-9347-8}, interhash = {0febe750780aa1bbf91d4b874a9745b3}, intrahash = {c0854fca60dcfbadd2dae42825264d33}, issn = {0969-6970}, journal = {Angiogenesis}, keywords = {Angiogenesis Combination Conjugates Hybrids Tumour Vascular agents disrupting myown therapy vasculature}, language = {English}, number = 3, pages = {503-524}, publisher = {Springer Netherlands}, timestamp = {2013-07-31T21:54:28.000+0200}, title = {Tumour vasculature targeting agents in hybrid/conjugate drugs}, url = {http://dx.doi.org/10.1007/s10456-013-9347-8}, volume = 16, year = 2013 }